retatrutide triple agonist glp-1 gip glucagon receptor Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide | GLP-1R/GIPR/GCGR ligand |

You could be on semaglutide for years and, once you stop taking it, stop feeling the impact of the weight-loss medication on your hunger levels

What happens after potential approval Assuming retatrutide eventually receives FDA approval, several practical questions arise for the research and clinical communities

The above meta-analyses comprised all clinical trials we could retrieve with our search 52,183,184,185,186,189,191,196,197,198,199,200

Hormone signaling, stomach motility, and nervous system sensitivity vary widely

When lifestyle changes arent giving you the results you want, GLP-1 medications could be worth a try

doi:10.1111/ijd.70133